PLOS ONE

TES-STUDY-P019

Clemmons DR, Miller S, Mamputu J-C. Safety and metabolic effects of tesamorelin in patients with type 2 diabetes. PLOS ONE. 2017. DOI: 10.1371/journal.pone.0179538. PMID: 28617838. NCT01264497. https://pmc.ncbi.nlm.nih.gov/articles/PMC5472315/

Study design

Record details

Design: Human clinical and physiological evidence

Evidence record

Endpoints, findings, and limitations

Limitations

This study record is an evidence-index entry. Interpret the design, material, population or model, endpoints, findings, and limitations only within the linked approved source and compound evidence map; do not transfer outcomes across compounds, materials, cohorts, or models.

Reports and sources

Reference ledger

P019Human clinical and physiological evidence

PLOS ONE

Clemmons DR, Miller S, Mamputu J-C. Safety and metabolic effects of tesamorelin in patients with type 2 diabetes. Clemmons DR, Miller S, Mamputu J-C. Safety and metabolic effects of tesamorelin in patients with type 2 diabetes. PLOS ONE. 2017. DOI: 10.1371/journal.pone.0179538. PMID: 28617838. NCT01264497. https://pmc.ncbi.nlm.nih.gov/articles/PMC5472315/(2017). DOI: 10.1371/journal.pone.0179538